KDR and renal cell adenocarcinoma: Clinical trials of peptide-based vaccine therapy using the same VEGFR-derived/ HLA-A2402–restricted epitopes have been conducted to assess safety, tolerability, and potential clinical activity in patients with advanced gastrointestinal cancers and renal cell cancer [26, 27].